We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Global Cord Blood Corporation | NYSE:CO | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.9876 | 0 | 01:00:00 |
Blue Ocean Structure Investment Company Ltd. (“Blue Ocean”), a significant shareholder of Global Cord Blood Corporation (the “Company” or “Global Cord”) (NYSE: CO), today announced that the Eastern Caribbean Supreme Court in the High Court of Justice of the Virgin Islands (the “Court”) granted an injunction order (“the Order”) enjoining Golden Meditech Stem Cells (BVI) Company Limited (“Golden Meditech”) from taking any steps on a purported share charge from Blue Ocean and from pursuing the removal of Blue Ocean’s representative, Xu Ping, as a Director of Global Cord.
Blue Ocean, whose investment in Global Cord represents an ownership position of approximately 65% of the Company’s shares, has stated its intent to take all possible actions to stop Global Cord’s planned acquisition (the “Transaction”) of Cellenkos, Inc. (“Cellenkos”). In response to a distracting and fraudulent Schedule 13D filing made by Golden Meditech with the U.S. Securities and Exchange Commission on 23 May 2022, Blue Ocean filed an injunction order in the Court.
There will be a further hearing in respect of this Order on 16 June 2022 (the “Return Date"). Until after the Return Date or further Order of the Court, Golden Meditech must not:
Blue Ocean firmly believes the Transaction is not in the best interests of the Company or its shareholders due to the following reasons:
To safeguard the best interests of all shareholders of the Company, Blue Ocean intends to take all possible steps to prevent the proposed acquisition and protect shareholder value, including endeavoring to convene an EGM to pass a special resolution to terminate the proposed acquisition, elect a new slate of directors who will be accountable to all shareholders and to amend the Company’s Articles. Blue Ocean urges any shareholders of the Company who share any concerns regarding the proposed acquisition or the Board’s total disregard for shareholders to reach out immediately and join forces to protect all existing shareholders of the Company.
For more details, please refer to the 13D filing: https://www.sec.gov/Archives/edgar/data/0001467808/000110465922065445/tm2217130d1_sc13da.htm
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005242/en/
FTI Consulting Brad Newman (US) brad.newman@fticonsulting.com +12128505736
Rita Fong (Hong Kong) rita.fong@fticonsulting.com +85237684548
Rachel Hsueh (China) rachel.hsueh@fticonsulting.com +862123151065
1 Year Global Cord Blood Chart |
1 Month Global Cord Blood Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions